

EYE CHECK UP

DATE: - 30/01/23 NAME: - 3000pnil V- Rindhe AGE: - 3/179.

EXAMINATIONS: Moronal VISION.

Vision :-

	Nea	ar				Dista	nce					
Right Eye	6	6	ce	th		,	61	6	with	9	asses	5
Left Eye	61	6	Co	1329	per	0	61	6	7	10,0	hom	

Colour Vision (Tick Only)

NORMAL	
PARTIAL:RED/GREENDEFICIENCY	
COMPLETE:RED/GREEN DEFICIENCY	

DR RAJESH MAILAGIRE General Physician (MBBS) Reg No 2018/04/1055



HEALTH CHECK UP SUMMARY

Date	Refe	erred By	Location
31/01/23	medil	speel:	kharadi
	Gender	Age	SPO2
Rindhe	mode	31	100
Weight in Kg	BMI	Pulse (per min)	B P (mm of Hg)
67	20.2	98	
NO			
NO			
	31/01/23 Rindhe Weight in Kg 67	31/01/23	Gender Age Rindhe Male 31 Weight in Kg BMI Pulse (per min) 67 20.2 98

ADVICE/SUGGESTION:

NA

AZOUNA.

Signature of Medical Examiner

Dr. Shrideep Parab MBBS, DGO Obs & Gynecologist Reg. No. MMC 2013/11/3392:



Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range	
THYROID FUNCTION TEST (TFT)			
T3-Total	1.38	0.6 - 1.80	ng/mL
T4-Total	8.6	4.5 to 10.9	microgm/dl
TSH-Ultrasensitive	2.64	0.35 to 5.55	microU/mL
Method : CLIA			

Interpretation

TSH levels may be affected by acute illness and drugs like doapamine and gluco corticoids .

Low or undetectable TSH is suggestive of Grave~s disease

TSH between 5.5 to 15.0 with normal T3 T4 indicates impaired thyroid hormone or subclinical hypothyroidism or normal T3 T4 with slightly low TSH suggests subclinical Hyperthyroidism.

TSH suppression does not reflect severity of hyperthyroidism therefore , measurement of FT3 & FT4 is important.

FreeT3 is first hormone to increase in early Hyperthyroidism.

Only TSH level can prove to be misleading in patients on treatment. Therefore FreeT3, FreeT4 along with TSH should be checked. During pregnancy, T3 T4 can be high and TSH can be slightly low

END OF REPORT

DR. SAGAR RAJENDRA SHETE REG. NO. 083463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range	
LIPID PROFILE			
Cholesterol-Total Method : Spectrophotometry	180	Desirable level < 200 Borderline High 200-239 High >or = 240	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	175	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method : Serum, Direct measure-PEG	51	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method : Enzymatic selective protection	94	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method : Serum, Enzymatic (Calculated)	35	6 - 38	mg/dL
CHOL/HDL Ratio Method : Serum, Enzymatic	3.53	UP TO 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic	1.84	UP TO 3.5	
Note: 8-10 hours fasting sample is required.			

END OF REPORT

DR. SAGAR RAJENDRA SHETE REG. NO. 083463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range	
Blood Group Abo & Rh Typing, Blood			
Blood Group (ABO typing) Method : Manual-Hemagglutination	"B"		
RhD Factor (Rh Typing) Method : Manual hemagglutination	Positive		

END OF REPORT

DR. SAGAR RAJENDRA SHETE REG. NO. 0\$3463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:



Test Description	Value(s)	Reference Range	
GLYCOSYLATED HAEMOGLOBIN (GHB)	/ HBA1c)		
HbA1c (GLYCOSYLATED HEMOGLOBIN),	4.3		%
BLOOD			
Method : (HPLC, NGSP certified)			
Estimated Average Glucose :	76.71	-	mg/dL
Interpretation			
As per American Diabetes Association (ADA)			
Reference Group	HbA1c in %		
Non diabetic adults >=18 years	<5.7		
			

As per American Diabetes Association (ADA)					
Reference Group	HbA1c in %				
Non diabetic adults >=18 years	<5.7				
At risk (Prediabetes)	5.7 - 6.4				
Diagnosing Diabetes	>= 6.5				
	Age > 19 years				
	Goal of therapy: < 7.0				
Therapeutic goals for glycemic control	Action suggested: > 8.0				
	Age < 19 years				
	Goal of therapy: <7.5				

Note:

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.
- 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test De	scription	Value(s)	Reference Range	
	lovo			
9	212			
10	240			
11	269			
12	298			

END OF REPORT

REG. NO. 083463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF


Receiving Time: Jan 30, 2023

Sample ID:



Test Description	Value(s)	Reference Range	
LIVER FUNCTION TEST (LFT)			
Total Protein	6.89	6.6 - 8.3	g/dL
Method : Serum, Biuret, reagent blank end point			
Albumin	4.6	3.2 - 4.6	g/dL
Method : Serum, Bromocresol green			
Globulin	2.29	1.8 - 3.6	g/dL
Method : Serum, EIA			
A/G Ratio	2.01	1.2 - 2.2	
Method : Serum, EIA			
Bilirubin - Total	0.96	0.3 - 1.2	mg/dL
Method : Serum, Jendrassik Grof			
Bilirubin - Direct	0.20	< 0.2	mg/dL
Method : Serum, Diazotization			
Bilirubin - Indirect	0.76	0.1 - 1.0	mg/dL
Method : Serum, Calculated			
SGOT	22.2	Upto 40	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	24.9	Upto 42	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase	84	30 - 120	U/L
Method : PNPP-AMP Buffer/Kinetic			
GGT-Gamma Glutamyl Transpeptidae	35	< 55	U/L
Method : Serum, G-glutamyl-carboxy-nitoanilide			

END OF REPORT









Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID :

Test Description	Value(s)	Reference Range	
RENAL FUNCTION TEST			
Uric Acid Method : Serum, Uricase	5.02	3.2 - 7.2	mg/dL
Creatinine Method : Serum, Jaffe	1.1	0.4 - 1.4	mg/dL
Urea Method: Uricase	31	10 - 50	mg/dL
Blood Urea Nitrogen-BUN Method : Serum, Urease	14.49	8 - 23	mg/dL

Remark:

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

END OF REPORT

DR. SAGAR RAJENDRA SHETE REG. NO. 0\$3463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

DR. SAGAR RAJENDRA SHETE REG. NO. 083463 Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range	
Esr, Erythrocyte Sedimentation Rate			
ESR - Erythrocyte Sedimentation Rate	14	0-15	mm/hr

Method : EDTA Whole Blood, Manual Westergren

Interpretation:

- It indicates presence and intensity of an inflammatory process. It does not diagnose a specific disease. Changes in the ESR are more significant than the abnormal results of a single test.
- It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis and polymyalgia rheumatica.
- · It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

END OF REPORT







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:



Test Description	Value(s)	Reference Range		
Complete Blood Count				
WBC	6700	4000-10000	cell/cu.mm	
Neu%	57	50 - 70	%	
Lym%	38	20.0 - 40.0	%	
Mon%	03	3.0 - 12.0	%	
Eos%	02	0.5 - 5.0	%	
Bas%	00	0.0 - 1.0	%	
RBC	5.2	4.0 - 5.50	10^6/uL	
HGB	16.0	12.0 - 16.0	g/dL	
HCT	42.9	40.0 - 54.0	%	
MCV	82.1	78 - 100	fL	
MCH	31.0	27 - 34	pg	
MCHC	36.0	32 - 36	g/dL	
RDW-CV	13.3	11.0 - 16.0	%	
PLT	220	100 - 300	10^3/ul	
RBC	Normocytic no	Normocytic normochromic		
WBC	Within normal	Within normal limits		
Platelet	Adequate	Adequate		

END OF REPORT









Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range			
FASTING BLOOD SUGAR					
Glucose fasting Method : Fluoride Plasma-F, Hexokinase	88	Normal: 70 - 99 Impaired Tolerance: 100-125 Diabetes mellitus: >= 126 (on more than one occassion) (American diabetes association guidelines 2018)	mg/dL		
Urine Fasting	Absent				

END OF REPORT

REG. NO. 083463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL

Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range	
PPBS			
Blood Glucose-Post Prandial Method : Hexokinase	111	70 - 140	mg/dL
Urine Post Prandial	Absent		

END OF REPORT

DR. SAGAR RAJENDRA SHETE REG. NO. 083463







Age / Gender: 30 Yrs 11 M / Male

Mobile No.: 7774927566

Patient ID: 155

Source: MEDIWHEEL


Referral: SELF

Receiving Time: Jan 30, 2023

Sample ID:

Test Description	Value(s)	Reference Range	
URINE ROUTINE EXAMINATION			
Volume*	20	-	ml
Colour*	Pale Yellow		
Transparency (Appearance)*	Clear		
Deposit*	Absent		
Reaction (pH)*	6.5	4.5 - 8	
Specific Gravity*	1.015	1.010 - 1.030	
Chemical Examination (Automated Di	pstick Method) Urine		
Urine Glucose (sugar)*	Absent		
Urine Protein (Albumin)*	Absent		
Microscopic Examination Urine			
Pus Cells (WBCs)*	1-2	0 - 5	/hpf
Epithelial Cells*	2-3	0 - 4	/hpf
Red blood Cells*	Absent		/hpf
Crystals*	Absent		
Cast*	Absent		
Bacteria*	Absent		
Mucus Thread	Absent		

END OF REPORT









Patient Name: MR. SWAPNIL RINDHE Dt: 30 Jan 2023 Ref. By: MADYOASIS MEDICAL SERVICES 31 YEARS/M

X RAY CHEST PA VIEW

Both the lung fields are clear.

Both diaphragmatic domes have normal contours and positions.

Cardio-aortic silhouette has a normal appearance.

There is no evidence of any pleural effusion.

Bony thorax appears normal

CONCLUSION:

No obvious abnormality seen at present study.

Dr. GANESH SANAP
(MBBS,DMRD, DNB)
Consulting Radiologist



Name : MR. SWAPNIL RINDHE Age/Sex : 31 YEARS/M

Ref By : MADYOASIS MEDICAL SERVICES Date : 30 Jan 2023

2D ECHOCARDIOGRAPHY & COLOUR DOPPLER STUDY

Monday, January 30, 2023

Left Ventricle:

The left ventricle is normal in size. No e/o RWMA.

The left ventricular ejection fraction is normal .

Left Atrium:

The left atrium is normal size. No clot.

Right Ventricle:

The right ventricular is normal size. There is normal right Ventricular wall thickness.

Aorta:

The aortic root is normal.

Pulmonary Artery:

The Pulmonary artery is normal.

Pericardium:

There is no pericardial effusion. No calcification.

Aortic Valve:

The aortic valve is tri-leaflet with thin, pliable leaflets that move normally. There is no aortic Stenosis. No aortic regurgitation is present.

Mitral Valve:

The mitral valve leaflets are thin. Normal mitral gradients. There is no evidence of stenosis, prolapse. Diastolic flows are altered . No mitral regurgitation noted.

Tricuspid Valve:

The tricuspid valve leaflets are thin and pliable and the valve motion is normal. No tricuspid Regurgitation is noted.

Pulmonary Valve:

The pulmonary valve leaflets are thin and pliable and the valve motion is normal. No pulmonary Valvular regurgitation is noted.

Proximal Coronaries:

Not visualized.

IAS and IVS are intact.

M-MODE/2D PARAMETERS

AO	26	(23-37mm)
LA	26	(19-40mm)
RVD		(7-23mm)
LVD	40	(35-55mm)
LVS	31	(24-42mm)
IVS	8.3	(6-11mm)
LVPW	8.6	(6-11mm)
EF	55-60%	(50-70%)

Parameters in brackets indicate normal adult Values.

IMPRESSION:

- No e/o RWMA
- Normal EF.
- RA / RV not dilated.
- No e/o pulmonary hypertension
- Normal valves and velocities.
- No clot, vegetations or effusions.

Dr. GANESH SANAP (MBBS,DMRD, DNB) Consulting Radiologist FELLOW 2D ECHO (IAE)



Date: 30 Jan 2023 Patient Name : MR. SWAPNIL RINDHE

MADYOASIS MEDICAL SERVICES Age: 31 YEARS Sex: M Referred By

USG ABDOMEN AND PELVIS

Liver:

The liver is normal in size and echotexture. No focal lesion is seen. The intrahepatic biliary radicles are normal. The common bile duct and the portal vein appear normal.

Gall Bladder

The gall bladder is well distended. No e/o calculus seen . The wall thickness is normal.

The pancreas is normal in size and shape. No focal lesion or calcifications are seen within it. The pancreatic duct is normal.

Spleen

The spleen measures 10.1cm in size and is normal in echotexture. No focal lesion is seen.

Kidneys

The right kidney measures 9.6 x 4.1cm. The left kidney measures 9.8 x 5.4 cm. Both kidneys show normal parenchymal echo texture. The cortico-medullary differentiation is maintained bilaterally. The pelvicalyceal system is normal in both the kidneys.

Aorta/IVC

The aorta and IVC appear grossly normal. No ascites or lymphadenopathy is seen.

Urinary bladder

The bladder is well distended. The wall thickness is normal. No vesical calculus is seen.

The prostate corresponding to a weight of about 15 gms. No focal lesion or calcification is seen.

Impression

Normal study.



Dr. Ganesh Sanap MBBS, DMRD, DNB.



Name : MR.SWAPNIL RINDHE Age/Sex :31 Y/M

Ref By : MEDIOASIS MEDICAL SERVICE Date : 30/01/2023

ECG

Observations:

ECG done with in resting position with 10 leads.

Normal Sinus rhytm noted . NO E/O T wave inversion.

No obvious other abnormality.

ADv: CLINICAL CORRELATION.



Dr. MILIND SHINDE MBBS, DNB.